• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

6-羟基多巴胺单侧纹状体损伤后小鼠体内N-甲基-D-天冬氨酸受体重塑与神经元型一氧化氮合酶激活

NMDA receptor remodeling and nNOS activation in mice after unilateral striatal injury with 6-OHDA.

作者信息

de Carvalho Michele Barboza, Teixeira-Silva Bruna, Marques Suelen Adriani, Silva Andrea Alice, Cossenza Marcelo, da Cunha Faria-Melibeu Adriana, Serfaty Claudio Alberto, Campello-Costa Paula

机构信息

Laboratory of Neuroplasticity, Postgraduate Program in Neurosciences, Biology Institute, Fluminense Federal University, Niteroi, RJ, Brazil.

Laboratory of Neural Regeneration and Function, Department of Neurobiology, Federal Fluminense University, Niteroi, RJ, Brazil.

出版信息

Heliyon. 2024 Jul 4;10(14):e34120. doi: 10.1016/j.heliyon.2024.e34120. eCollection 2024 Jul 30.

DOI:10.1016/j.heliyon.2024.e34120
PMID:39130441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11315104/
Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by selective dopaminergic loss. Non dopaminergic neurotransmitters such as glutamate are also involved in PD progression. NMDA receptor/postsynaptic density protein 95 (PSD-95)/neuronal nitric oxide synthase (nNOS) activation is involved in neuronal excitability in PD. Here, we are focusing on the evaluating these post-synaptic protein levels in the 6-OHDA model of PD. Adult male C57BL/6 mice subjected to unilateral striatal injury with 6-OHDA were assessed at 1-, 2-, or 4-weeks post-lesion. Animals were subjected to an apomorphine-induced rotation test followed by the analysis of protein content, synaptic structure, and NOx production. All biochemical analysis was performed comparing the control lesioned sides of the same animal. 6-OHDA mice exhibited contralateral rotation activity, difficulties in coordinating movements, and changes in Iba-1 and glial fibrillary acidic protein (GFAP) expression during the whole period. At one week of survival, the mice showed a shift in NMDA composition, favoring the GluN2A subunit and increased PSD95 and nNOS expression and NOx formation. After two-weeks, a decrease in the total number of synapses was observed in the lesioned side. However, the number of excitatory synapses was increased with a higher content of GluN1 subunit and PSD95. After four weeks, NMDA receptor subunits restored to control levels. Interestingly, NOx formation in the serum increased. This study reveals, for the first time, the temporal course of behavioral deficits and glutamatergic synaptic plasticity through NMDAr subunit shift. Together, these data demonstrate that dopamine depletion leads to a fine adaptive response over time, which can be used for further studies of therapeutic management adjustments with the progression of PD.

摘要

帕金森病(PD)是一种以选择性多巴胺能神经元缺失为特征的进行性神经退行性疾病。谷氨酸等非多巴胺能神经递质也参与帕金森病的进展。NMDA受体/突触后致密蛋白95(PSD - 95)/神经元型一氧化氮合酶(nNOS)的激活与帕金森病中的神经元兴奋性有关。在此,我们着重评估帕金森病6 - 羟基多巴胺(6 - OHDA)模型中这些突触后蛋白的水平。对成年雄性C57BL / 6小鼠进行单侧纹状体6 - OHDA损伤,并在损伤后1周、2周或4周进行评估。对动物进行阿扑吗啡诱导的旋转试验,随后分析蛋白质含量、突触结构和一氧化氮(NOx)生成。所有生化分析均在同一动物的对照侧和损伤侧之间进行比较。6 - OHDA小鼠在整个期间表现出对侧旋转活动、运动协调困难以及离子钙结合衔接分子1(Iba - 1)和胶质纤维酸性蛋白(GFAP)表达的变化。在存活1周时,小鼠的NMDA组成发生变化,有利于GluN2A亚基,并且PSD95和nNOS表达以及NOx形成增加。两周后,在损伤侧观察到突触总数减少。然而,兴奋性突触的数量增加,GluN1亚基和PSD95的含量更高。四周后,NMDA受体亚基恢复到对照水平。有趣的是,血清中的NOx生成增加。本研究首次揭示了行为缺陷和通过NMDAr亚基转变的谷氨酸能突触可塑性的时间进程。总之,这些数据表明多巴胺耗竭会随着时间导致精细的适应性反应,这可用于帕金森病进展过程中治疗管理调整的进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/f1ecddb7c0ea/mmcfigs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/2b50201eb9a6/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/e0d5099bd025/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/5284505b68d0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/a9d2fae54c0e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/d374298877ea/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/7c0a513918c4/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/e05a8ed31a39/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/3b0bec788806/mmcfigs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/cc5d9a8e26dc/mmcfigs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/f1ecddb7c0ea/mmcfigs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/2b50201eb9a6/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/e0d5099bd025/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/5284505b68d0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/a9d2fae54c0e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/d374298877ea/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/7c0a513918c4/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/e05a8ed31a39/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/3b0bec788806/mmcfigs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/cc5d9a8e26dc/mmcfigs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d77/11315104/f1ecddb7c0ea/mmcfigs3.jpg

相似文献

1
NMDA receptor remodeling and nNOS activation in mice after unilateral striatal injury with 6-OHDA.6-羟基多巴胺单侧纹状体损伤后小鼠体内N-甲基-D-天冬氨酸受体重塑与神经元型一氧化氮合酶激活
Heliyon. 2024 Jul 4;10(14):e34120. doi: 10.1016/j.heliyon.2024.e34120. eCollection 2024 Jul 30.
2
Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson's disease.帕金森病大鼠模型纹状体中 N-甲基-D-天冬氨酸受体表面表达的变化
Drug Des Devel Ther. 2014 Jan 17;8:165-73. doi: 10.2147/DDDT.S51559. eCollection 2014.
3
NMDA receptors are altered in the substantia nigra pars reticulata and their blockade ameliorates motor deficits in experimental parkinsonism.NMDA 受体在黑质网状部发生改变,其阻断可改善帕金森病动物模型的运动缺陷。
Neuropharmacology. 2020 Sep 1;174:108136. doi: 10.1016/j.neuropharm.2020.108136. Epub 2020 May 29.
4
Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson's disease.和厚朴酚在逆转帕金森病小鼠模型运动缺陷和神经元变性中的保护和治疗作用。
Pharmacol Rep. 2018 Aug;70(4):668-676. doi: 10.1016/j.pharep.2018.01.003. Epub 2018 Jan 12.
5
Therapeutic effects of honokiol on motor impairment in hemiparkinsonian mice are associated with reversing neurodegeneration and targeting PPARγ regulation.厚朴酚对偏侧帕金森病小鼠运动障碍的治疗作用与逆转神经退行性变和靶向过氧化物酶体增殖物激活受体γ(PPARγ)调节有关。
Biomed Pharmacother. 2018 Dec;108:254-262. doi: 10.1016/j.biopha.2018.07.095. Epub 2018 Sep 14.
6
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.痕量胺相关受体1对实验性帕金森病、左旋多巴反应性及谷氨酸能神经传递的调节作用
J Neurosci. 2015 Oct 14;35(41):14057-69. doi: 10.1523/JNEUROSCI.1312-15.2015.
7
Design and synthesis of benzo[d]thiazol-2-yl-methyl-4-(substituted)-piperazine-1-carbothioamide as novel neuronal nitric oxide inhibitors and evaluation of their neuroprotecting effect in 6-OHDA-induced unilateral lesioned rat model of Parkinson's disease.苯并[d]噻唑-2-基-甲基-4-(取代)-哌嗪-1-碳硫酰胺的设计与合成作为新型神经元型一氧化氮合酶抑制剂及其在单侧 6-羟基多巴胺致帕金森病大鼠模型中的神经保护作用评价。
Biomed Pharmacother. 2022 Dec;156:113838. doi: 10.1016/j.biopha.2022.113838. Epub 2022 Oct 20.
8
The modulatory effect of 100 Hz electroacupuncture on striatal synaptic plasticity in unilateral lesioned 6-OHDA rats.100Hz 电针对单侧损毁 6-OHDA 大鼠纹状体突触可塑性的调制作用。
Brain Res Bull. 2022 Aug;186:123-135. doi: 10.1016/j.brainresbull.2022.06.004. Epub 2022 Jun 10.
9
Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism.谷氨酸能皮质-纹状体突触功能改变导致帕金森病慢性模型中的输出通路异常。
Neurobiol Dis. 2011 Mar;41(3):591-604. doi: 10.1016/j.nbd.2010.10.013. Epub 2010 Oct 21.
10
Puncta of Neuronal Nitric Oxide Synthase (nNOS) Mediate NMDA Receptor Signaling in the Auditory Midbrain.神经元型一氧化氮合酶(nNOS)的突触参与听觉中脑 NMDA 受体信号转导。
J Neurosci. 2019 Jan 30;39(5):876-887. doi: 10.1523/JNEUROSCI.1918-18.2018. Epub 2018 Dec 7.

本文引用的文献

1
Synaptic determinants of cholinergic interneurons hyperactivity during parkinsonism.帕金森病期间胆碱能中间神经元活动亢进的突触决定因素。
Front Synaptic Neurosci. 2022 Sep 6;14:945816. doi: 10.3389/fnsyn.2022.945816. eCollection 2022.
2
Enteric glial cell reactivity in colonic layers and mucosal modulation in a mouse model of Parkinson's disease induced by 6-hydroxydopamine.6-羟多巴胺诱导的帕金森病小鼠模型结肠层肠胶质细胞反应和黏膜调节。
Brain Res Bull. 2022 Sep;187:111-121. doi: 10.1016/j.brainresbull.2022.06.013. Epub 2022 Jun 28.
3
Pathophysiological Features of Nigral Dopaminergic Neurons in Animal Models of Parkinson's Disease.
帕金森病动物模型中黑质多巴胺能神经元的病理生理学特征。
Int J Mol Sci. 2022 Apr 19;23(9):4508. doi: 10.3390/ijms23094508.
4
Striatal glutamatergic hyperactivity in Parkinson's disease.帕金森病中纹状体谷氨酸能功能亢进
Neurobiol Dis. 2022 Jun 15;168:105697. doi: 10.1016/j.nbd.2022.105697. Epub 2022 Mar 18.
5
Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state.人类中脑的单细胞测序揭示胶质细胞的激活和帕金森特异性神经元状态。
Brain. 2022 Apr 29;145(3):964-978. doi: 10.1093/brain/awab446.
6
Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response.单侧纹状体 6-羟多巴胺损伤在小鼠模型中的研究:非运动表型与神经胶质反应的深入探讨。
Int J Mol Sci. 2021 Oct 26;22(21):11530. doi: 10.3390/ijms222111530.
7
Changes in synaptic proteins of the complex PSD-95/NMDA receptor/nNOS and mitochondrial dysfunction after levocabastine treatment.左卡巴斯汀治疗后 PSD-95/NMDA 受体/nNOS 复合物中突触蛋白的变化和线粒体功能障碍。
Neurochem Int. 2021 Sep;148:105100. doi: 10.1016/j.neuint.2021.105100. Epub 2021 Jun 15.
8
The Contribution of Microglia to Neuroinflammation in Parkinson's Disease.小胶质细胞在帕金森病神经炎症中的作用。
Int J Mol Sci. 2021 Apr 28;22(9):4676. doi: 10.3390/ijms22094676.
9
nNOS-mediated protein-protein interactions: promising targets for treating neurological and neuropsychiatric disorders.神经元型一氧化氮合酶介导的蛋白质-蛋白质相互作用:治疗神经和神经精神疾病的潜在靶点。
J Biomed Res. 2020 Dec 10;35(1):1-10. doi: 10.7555/JBR.34.20200108.
10
Novel Therapeutic Approach for Excitatory/Inhibitory Imbalance in Neurodevelopmental and Neurodegenerative Diseases.新型治疗策略治疗神经发育和神经退行性疾病中的兴奋/抑制失衡。
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:701-721. doi: 10.1146/annurev-pharmtox-032320-015420. Epub 2020 Sep 30.